Clinical Grade Treg Isolation and Expansion
Author Information
Author(s): Peters Jorieke H., Preijers Frank W., Woestenenk Rob, Hilbrands Luuk B., Koenen Hans J. P. M., Joosten Irma
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
Can we improve the purity and functionality of regulatory T cells (Treg) isolated for immunotherapy using GMP protocols?
Conclusion
The study demonstrates that high purity Treg can be achieved through specific isolation and expansion techniques, making them suitable for clinical applications.
Supporting Evidence
- CliniMACS isolation procedures led to 40–60% pure Treg populations.
- Depletion of CD127pos cells improved Treg purity to approximately 90%.
- Expanded Treg populations showed potent suppressive capacity.
Takeaway
This research shows how to get really pure immune cells that help control other immune responses, which is important for treating diseases like autoimmunity and for organ transplants.
Methodology
Treg were isolated from leukapheresis products using CliniMACS and expanded with polyclonal or alloantigen stimulation.
Potential Biases
Potential contamination of Treg populations with non-regulatory T cells could affect outcomes.
Limitations
The study primarily focuses on the isolation and expansion methods without extensive clinical trial data.
Participant Demographics
Healthy donors provided leukapheresis products for Treg isolation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website